v3.26.1
Asset Purchase Agreement - Schedule of Development Milestones (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
First Patient Dosed in Phase 2 Initiated with Frunexian or EP-7327 [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
$ 500,000
First Patient Dosed in Phase 1 Initiated with EP-7327 [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
500,000
First Patient Dosed in Phase 3 Initiated with Frunexian or EP-7327 [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
1,000,000
FDA Approval of New Drug Application for Frunexian or EP-7327 [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
6,000,000
First Patient Dosed in the First Clinical Trial with CAD-1005 [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
2,000,000
First regulatory filing approval to market a pharmaceutical product for human use containing a Compound that is covered by a patent owned or licensed by Veralox (the “Product”) in the United States [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
8,000,000
First regulatory filing approval to market a Product outside the United States [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
2,000,000
Regulatory filing approval to market a Product for a subsequent indication in the United States [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
2,000,000
Regulatory filing approval to market a Product for a subsequent indication outside the United States [Member]
Schedule of Contingent Milestone Payments [Line Items]
Milestone payment
$ 1,000,000
X
- References
No definition available.
+ Details
Name:
cvkd_AssetPurchaseAgreementScheduleofDevelopmentMilestonesDetailsLineItems
Namespace Prefix:
cvkd_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The amount represents payments of milestones.
+ References
No definition available.
+ Details
Name:
cvkd_PaymentsOfMilestones
Namespace Prefix:
cvkd_
Data Type:
xbrli:monetaryItemType
Balance Type:
debit
Period Type:
duration
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstPatientDosedInPhase2InitiatedWithFrunexianOrEP7327Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstPatientDosedInPhase1InitiatedWithEP7327Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstPatientDosedInPhase3InitiatedWithFrunexianOrEP7327Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FDAApprovalOfNewDrugApplicationForFrunexianOrEP7327Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstPatientDosedInTheFirstClinicalTrialWithCAD1005Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstUSFDAApprovalForSellerPatentedVeriloxProductMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_FirstRegulatoryFilingApprovalToMarketAProductOutsideTheUnitedStatesMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_RegulatoryFilingApprovalToMarketAProductForASubsequentIndicationInTheUnitedStatesMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_TypeOfArrangementAxis=cvkd_RegulatoryFilingApprovalToMarketAProductForASubsequentIndicationOutsideTheUnitedStatesMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: